About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Evaluation of the PreCursor-M+® in CIN2 | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT06403618

Evaluation of the PreCursor-M+® in CIN2

The goal of this observational study is to to evaluate the accuracy and sensitivity of PreCursor-M+ on a post-aliquot of liquid-based cytology (LBC) cervical samples (biopsy) obtained by physicians in...

Lead sponsor: European Institute of Oncology•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Anna Daniela Iacobone

CONTACT

+39 0294371088 annadaniela.iacobone@ieo.it

Sponsors

Lead Sponsor

European Institute of Oncology

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•1. age at diagnosis of 18 years or older;
•2. histological confirmation of CIN2 after colposcopic-guided cervical biopsy or conservative surgical treatment, including loop electrosurgical excision procedure (LEEP) and laser conization;
•3. known HPV test result at baseline;
•4. ability to understand and sign the informed consent;
•5. written informed consent given.

Exclusion Criteria

•1. unknown HPV test result at diagnosis;
•2. vulnerable patients.

Related studies

Active Not RecruitingNA

Effectiveness of Cervical Screening in HPV Vaccinated Women

NCT02149030 · Cervical Intraepithelial Neoplasia Grade 2/3

Active Not Recruiting

Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples

NCT03064087 · Cervical Intraepithelial Neoplasia Grade 2/3

COMPLETEDPhase 2

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

NCT06439433 · Cervical Intraepithelial Neoplasia Grade 2, Papillomavirus Infections, and more

Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions

NCT05851079 · Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Lesion

COMPLETEDPhase 1

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

NCT02354534 · Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 23, 2025Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment100

Start dateJun 2024

Last updatedMay 23, 2025

Condition

Cervical Intraepithelial Neoplasia Grade 2

Locations shown

European Institute of Oncology, Milan,

Milan

European Institute of Oncology

Milan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 23, 2025Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions